Bora Pharmaceuticals announced its financial report for the previous year, revealing an average gross profit margin of 49%, a 20% increase from the previous year. The annual net profit after tax reached NT$3.03 billion, translating to approximately NT$30.2 earnings per share (EPS), marking the first time Bora has earned three times its share capital in a single year since its inception. The Board of Directors of Bora also approved the distribution of earnings for the fiscal year 2023, proposing a cash dividend of NT$12 per share, marking the highest dividend payout in the company's history. 

Looking specifically at the fourth-quarter profits from last year, Bora's EPS was NT$5.64. 

Bora indicated that its CDMO business produced approximately 1.4 billion doses of pharmaceuticals last year, including the commercial launch of six products. Additionally, its biologics manufacturing site successfully completed 14 customer-initiated development projects. Moreover, significant achievements were made in expanding into new business areas, with a total of 40 new contracts secured for small and large molecule products and services throughout 2023, contributing to sustained momentum in revenue growth and profitability. 

Bora's Chairman, Bobby Sheng, emphasized the ongoing efforts to strengthen its product portfolio, with both major business segments complementing each other to provide the company with a more stable cash flow. In early 2024, the Board of Directors approved the acquisition of Upsher-Smith, a pharmaceutical company based in Minnesota, USA. This acquisition is pending approval from relevant US regulatory authorities. Upon completion of all pre-closing requirements, Bora Group will immediately gain access to a newly expanded manufacturing facility in Minnesota, which has already been inspected and approved by the US FDA, with a total production capacity of 3.5 billion doses. This acquisition will propel Bora Group to become one of the largest oral solid dose manufacturers in the United States.